



## Joint Working Executive Summary

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

<b>Project title</b>	Observations of ongoing management of stroke patients discharged from healthcare services across the Oxford AHSN footprint during the COVID-19 pandemic.
<b>Project partners</b>	Oxford AHSN Bayer plc
<b>Project summary</b>	<p>The aim of the project is to provide an in-depth understanding of how the initial phase of the COVID-19 planning impacted the provision of post-acute stroke services using a combination of data analytics and qualitative analysis.</p> <p>This will enable the NHS to identify potential solutions and system changes to optimise current and future patient care.</p>
<b>Expected benefits to patients, the NHS and Bayer</b>	<p><b>Patients</b></p> <ul style="list-style-type: none"><li>• Understanding the impact of early discharge from acute stroke units and Emergency Departments to inform second wave planning</li><li>• Opportunity for patients and carers to give feedback on their experiences during this time to inform future planning of stroke services</li><li>• Potential improvement to stroke services</li></ul> <p><b>NHS</b></p> <ul style="list-style-type: none"><li>• An understanding and estimation of the unmet need in stroke patients discharged during the early phases of the COVID-19 pandemic</li><li>• Root cause analysis to enable identification of factors that need to be addressed</li><li>• Qualitative and quantitative feedback to inform planning of future stroke services as part of the NHS Reset</li><li>• Outputs of the project can be shared more widely across the AHSN and GIRFT networks to inform their work programmes</li></ul> <p><b>Bayer</b></p> <ul style="list-style-type: none"><li>• The opportunity to work closely with the NHS to identify and build solutions to stroke delivery as part of the NHS Reset</li><li>• To co-create a framework for in-depth analysis of issues and solution identification that can be used in other health economies and translated into other disease areas</li></ul>

	<ul style="list-style-type: none"><li>• Demonstrate Bayer's value beyond our pharmaceutical offerings and position ourselves as a trusted partner for future projects</li></ul>
<b>Start date</b>	September 2020

Date of Reapproval: September 2021

Job bag number: RP-UN-CAR-GB-0043